Compounds, compositions, and methods
AssigneeCHDI Foundation, Inc.
InventorsTasir Haque, Michel Maillard, Gareth Brace, George Ballantyne, Elizabeth Frush, Kim Hirst, Katherine Jones, Emanuela Gancia, Chris Lock, Cole Clissold
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to small molecule inhibitors of MutSβ protein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
Claims34
A compound of Formula I:
- or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:
- n is 0, 1, 2, 3, or 4;
- m is 0, 1, 2, 3, 4, or 5;
- p is 0, 1, 2, 3, 4, or 5;
- q is 0, 1, 2, 3, or 4;
- provided that p+q is 2, 3, 4, or 5;
- L is —NH—, —O—, —CH2—, —NHCH2—, —OCH2—, or —CH2CH2—;
- X1 is CR5 or N;
- R1 is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R1a and R2a are each independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —O—R11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R2 is halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —O—R11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —O—R11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R5 is hydrogen, C1-6 alkyl, or —N(R11)2;
- each R10 is independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —OR11, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl;
- and
- each R11 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl;
- provided that:
- when L is —NH—, R3 and R4 are both hydrogen, and the moiety
- then the moiety
-8. (canceled)
(canceled)
(canceled)
A method for treating a disease or disorder modulated, at least in part, by MutSβ, in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:
- n is 0, 1, 2, 3, or 4;
- m is 0, 1, 2, 3, 4, or 5;
- p is 0, 1, 2, 3, 4, or 5;
- q is 0, 1, 2, 3, or 4;
- provided that p+q is 2, 3, 4, or 5;
- L is —NH—, —O—, —CH2—, —NHCH2—, —OCH2—, or —CH2CH2—;
- X1 is O, N, or CH;
- provided that when X1 is O, then R1 is absent;
- R1, when present, is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R1a and R2a are each independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R2 is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR1C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- each R10 is independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —OR11, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl;
- and
- each R11 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl.
A method for inhibiting the activity of MutSβ, the method comprising administering to a subject in need thereof, an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:
- n is 0, 1, 2, 3, or 4;
- m is 0, 1, 2, 3, 4, or 5;
- p is 0, 1, 2, 3, 4, or 5;
- q is 0, 1, 2, 3, or 4;
- provided that p+q is 2, 3, 4, or 5;
- L is —NH—, —O—, —CH2—, —NHCH2—, —OCH2—, or —CH2CH2—;
- X1 is O, N, or CH;
- provided that when X1 is O, then R1 is absent;
- R1, when present, is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R1a and R2a are each independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R2 is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- each R10 is independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —OR11, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl;
- and
- each R11 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl.
A method for treating a neurodegenerative or neurological disease or disorder, the method comprising administering to a subject in need thereof, an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein:
- n is 0, 1, 2, 3, or 4;
- m is 0, 1, 2, 3, 4, or 5;
- p is 0, 1, 2, 3, 4, or 5;
- q is 0, 1, 2, 3, or 4;
- provided that p+q is 2, 3, 4, or 5;
- L is —NH—, —O—, —CH2—, —NHCH2—, —OCH2—, or —CH2CH2—;
- X1 is O, N, or CH;
- provided that when X1 is O, then R1 is absent;
- R1, when present, is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R1a and R2a are each independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R2 is hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 R10;
- each R10 is independently halo, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, heterocyclyl, aryl, heteroaryl, —OR11, —N(R11)2, —C(O)R11, —C(O)OR11, —S—R11, S(O)R11, —S(O)2R11, —NR11S(O)R11, —NR11S(O)2R11, —S(O)N(R11)2, —S(O)2N(R11)2, —NR11S(O)N(R11)2, —NR11S(O)2N(R11)2, —NR11C(O)N(R11)2, —C(O)N(R11)2, —NR11C(O)R11, —OC(O)N(R11)2, or —NR11C(O)OR11;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, heteroaryl, or heterocyclyl;
- and
- each R11 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
- wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with 1-5 halo, cyano, —NO2, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl.
-36. (canceled)
Dependencies are inferred from the claim text.